PRE
Prenetics Global Limited
PRE lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
PRE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Weak |
PRE's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
PRE PE Valuation
PRE has no meaningful PE right now: it lost money over the past year.
PRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
PRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.16 | -$0.29 |
| Q1 2026 | -$4.58 | -$0.77 |
| Q4 2025 | -$4.02 | -$0.31 |
| Q3 2025 | -$3.56 | +$0.26 |
| Q2 2025 | -$3.87 | +$0.27 |
| Q1 2025 | -$3.81 | +$1.51 |
| Q4 2024 | -$3.71 | +$1.90 |
| Q3 2024 | -$3.82 | +$0.24 |
PRE is still losing money, but far less than before: $4.16 per share over the past year, against $96.85 at its worst in mid-2022.
PRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $46.5M | +163% |
| Q1 2026 | $36M | +108% |
| Q4 2025 | $36.6M | +249% |
| Q3 2025 | $23.6M | +203% |
| Q2 2025 | $17.7M | +198% |
| Q1 2025 | $17.3M | +170% |
| Q4 2024 | $10.5M | +99% |
| Q3 2024 | $7.8M | +59% |
PRE's revenue has grown year over year for eight quarters in a row: $46M last quarter, up 163% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -47% | +9.8 points |
| Q1 2026 | -27% | +34 points |
| Q4 2025 | -34% | +124 points |
| Q3 2025 | -26% | +126 points |
| Q2 2025 | -57% | +122 points |
| Q1 2025 | -61% | +81 points |
| Q4 2024 | -158% | +59 points |
| Q3 2024 | -152% | +114 points |
PRE's operating margin was −47% last quarter, up 9.8 points from the same quarter a year ago.
PRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | -$12.1M | -$12.1M |
| Q4 2025 | -$22M | -$22M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
PRE's free cash flow was −$34M over the past year, against $0 the year before.
PRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +284K shares |
| 1 year | +30% | +4M shares |
| 3 years | +63% | +6.7M shares |
| 5 years | +561% | +14.7M shares |
PRE has 17M diluted shares, up 30% from a year ago, despite $40M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $26.9M |
| Q1 2026 | $13.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PRE spent $40M buying back its own shares over the past year, after none the year before.
PRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | 50.8x | High |
| Q1 2021 | 2.2x | Moderate |
| Q4 2020 | 0.5x | Very low |
PRE's net debt is more than 20 years of its operating earnings (EBITDA).
PRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.2 | Neutral |
| Stochastic | 13.9 | Oversold |
PRE's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
PRE PE vs Healthcare Sector
PRE has no meaningful PE right now: it lost money over the past year.
PRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.9 | 12% below |
| 20 week MA | $19.9 | 16% below |
| 50 week MA | $18.8 | 11% below |
| 100 week MA | $13.4 | 24% above |
| 200 week MA | $10.7 | 56% above |
PRE has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 56% above its 200-week average.
PRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $120.6 | $31.5 | -74% |
| 2023 | $31.5 | $5.91 | -81% |
| 2024 | $5.91 | $5.70 | -3.6% |
| 2025 | $5.70 | $16.9 | +196% |
| 2026 YTD | $16.9 | $16.7 | -0.9% |
PRE's yearly returns have swung widely, from +196% in 2025 to −81% in 2023. It's down 0.9% so far in 2026.